Ian Ingram on Muck Rack

Ian Ingram

Verified
New York
As seen in: MedPage Today, MSN, Royal Society of Chemistry, Veterans Today, Chemistry World, ONCOLOGY journal, HealthLeaders, Sail-World, Ex Bulletin, NewsBeezer
Deputy Managing Editor MedPage Today
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ian

Contact Ian, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

New AML regimen for unfit patients gets FDA's blessing

|
By Ian Ingram Verified
| MSN Verified
Ian Ingram The FDA on Wednesday approved a new all-oral regimen for newly diagnosed acute myeloid leukemia (AML) in patients ineligible for intensive chemotherapy.
Open in Who Shared View Duplicates (3) Issue with article?

GLP-1s and hepatic events; 'Shame, taboo, hygiene'; treating late-onset IBD

|
By Ian Ingram Verified
| MSN Verified
Ian Ingram Among U.S. adults with diabetes and steatotic liver disease in the All of Us cohort, new use of a GLP-1 receptor agonist was linked with a 38% to 42% lower risk of hepatic events over nearly 3 years of median follow-up. ( American Journal of Gastroenterology ) Measures of frailty and functional capacity in cirrhosis patients can predict future hospitalization , according to a prospective cohort study.
Open in Who Shared View Duplicates (3) Issue with article?

FDA expands Stelara approval; liver cancer blood test; pharmacotherapy for MASLD

|
By Ian Ingram Verified
| MSN Verified
Ian Ingram The FDA expanded the approval of ustekinumab (Stelara) in Crohn's disease to include the treatment of kids as young as 2 years, Johnson & Johnson announced. High clinical remission rates (98%) at approximately 5 years were reported with guselkumab (Tremfya) maintenance in Crohn's disease, long-term follow-up of the phase II GALAXI-1 trial showed.
Open in Who Shared Issue with article?
See all 63 licensed articles (577 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified